Core F: Biomarker/Neuroimaging Core

摘要-生物标志物/神经影像核心 拟议的生物标记物/神经成像核心在Rush阿尔茨海默病研究中的总体目标 中心(Rush ADRC)是建立Rush ADRC参与者的神经成像数据资源，并 辅助研究，并提供神经成像专业知识，以促进高质量、尖端的外部资助 从正常衰老到轻度认知障碍(MCI)再到早期阶段的研究 阿尔茨海默病(AD)和其他痴呆症。具体地说，Biomarker/神经成像核心将整合 高质量、多模式、纵向体内和体外脑磁共振成像(MRI)数据和 最新收集的正电子发射断层扫描(PET)数据，分别来自Rush ADRC和 资助的研究，全部基于最先进的、统一的数据采集协议。生物标记物/神经成像 CORE将对体内和体外MRI数据进行彻底的质量检查和详细处理 生成关于宏观结构、微观结构、化学和功能大脑的丰富输出的数据库 老年人大脑血管和神经退行性变过程的特征和新的分类器。 将通过扫描(标准化集中)进行PET数据的质量检查和处理 阿尔茨海默氏症和相关痴呆症的神经成像)。Rush ADRC的生物标记物/神经成像核心将 将所有脑部MRI和PET数据和处理结果广泛分发给内部和外部的研究人员 Rush ADRC，并将提供神经成像专业知识，支持正常衰老、认知能力的研究努力 精神衰退、轻度认知障碍、阿尔茨海默病及相关痴呆。建议的生物标志物/神经成像核心 将建立在Rush ADRC的优势基础上，包括A)对登记的人进行纵向临床评估 没有痴呆，B)纵向死前生物液收集，以及C)死后生物显微镜收集 来自大量的人，其中许多人没有痴呆症。生物标记物/神经成像的贡献 CORE将刺激研究：A)开发新的基于MRI的年龄相关神经病理分类器，B) 阐明支持认知和运动健康或导致衰退的大脑机制，C)评估 风险因素对大脑的影响，D)将神经成像与多水平组学联系起来，E)支持发展和 基于外周血液和视网膜成像的新生物标志物的验证，以及F)确定 认知老化相关结果的种族/民族差异的不同大脑特征。

ABSTRACT – BIOMARKER/NEUROIMAGING CORE The overall goal of the proposed Biomarker/Neuroimaging Core in the Rush Alzheimer’s Disease Research Center (Rush ADRC) is to build a resource of neuroimaging data on participants of the Rush ADRC and ancillary studies, and provide neuroimaging expertise to facilitate high quality, cutting edge, externally funded research focusing on the transition from normal aging to mild cognitive impairment (MCI) to the earliest stages of Alzheimer’s disease (AD) and other dementias. Specifically, the Biomarker/Neuroimaging Core will integrate high quality, multi-modal, longitudinal in-vivo and ex-vivo brain magnetic resonance imaging (MRI) data and newly collected positron emission tomography (PET) data from participants of the Rush ADRC and separately funded studies, all based on state-of-the-art, uniform data acquisition protocols. The Biomarker/Neuroimaging Core will perform thorough quality checks and detailed processing of the in-vivo and ex-vivo MRI data in the database to generate rich output on macro-structural, micro-structural, chemical, and functional brain characteristics and on novel classifiers of vascular and neurodegenerative processes in the older adult brain. Quality checks and processing of the PET data will be conducted by SCAN (Standardized Centralized Alzheimer’s and Related Dementias Neuroimaging). The Biomarker/Neuroimaging Core of the Rush ADRC will widely distribute all brain MRI and PET data and processing results to investigators within and outside of the Rush ADRC, and will provide neuroimaging expertise in support of research efforts in normal aging, cognitive decline, mild cognitive impairment, AD and related dementias. The proposed Biomarker/Neuroimaging Core will build upon strengths of the Rush ADRC including A) longitudinal clinical assessment of persons who enroll without dementia, B) longitudinal ante-mortem biofluid collection, and C) post-mortem biospecimen collection from large numbers of persons, many without dementia. The contributions of the Biomarker/Neuroimaging Core will stimulate research that A) develops novel MRI-based classifiers of age-related neuropathologies, B) elucidates brain mechanisms supporting cognitive and motor health or leading to decline, C) evaluates the effects of risk factors on the brain, D) links neuroimaging to multi-level omics, E) supports the development and validation of novel biomarkers based on peripheral blood and retinal imaging, and F) ascertains the role of various brain characteristics in racial/ethnic disparities of cognitive aging related outcomes.